New stem cell mix aims to make transplants safer for blood cancer patients
NCT ID NCT05316701
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a special mix of stem cells and immune cells from a matched donor, designed to reduce a serious side effect called graft-versus-host disease. The study compares Orca-T to the standard stem cell transplant in 187 patients, tracking how many are alive and free of moderate or severe graft-versus-host disease after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Orca-T (a mix of stem cells and immune cells from a donor)
- What this could lead to
- If it works, this could lead to a safer stem cell transplant with fewer severe side effects, improving survival and quality of life for people with blood cancers.
- What could go wrong
- This is still a phase 3 trial, so results are not yet final. The treatment may not work better than standard care, and there are risks like infection or graft failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Oregon Health & Sciences University - Knight Cancer Institute
Portland, Oregon, 97239, United States
-
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90095, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37239, United States
-
Stanford Health Care
Stanford, California, 94305, United States
-
UC Davis
Sacramento, California, 95817, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of Michigan Health System - Michigan Medicine
Ann Arbor, Michigan, 48109, United States
-
University of Utah
Salt Lake City, Utah, 84112, United States
-
Vanderbilt University
Nashville, Tennessee, 37232, United States
-
Weill Cornell Medicine - New York-Presbyterian Hospital
New York, New York, 10021, United States
-
Winship Cancer Institute - Emory University
Atlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?